key: cord-0964054-gdkph7hj authors: Valley‐Omar, Ziyaad; Tempia, Stefano; Hellferscee, Orienka; Walaza, Sibongile; Variava, Ebrahim; Dawood, Halima; Kahn, Kathleen; McMorrow, Meredith; Pretorius, Marthi; Mtshali, Senzo; Mamorobela, Ernest; Wolter, Nicole; Venter, Marietjie; von Gottberg, Anne; Cohen, Cheryl; Treurnicht, Florette K. title: Human respiratory syncytial virus diversity and epidemiology among patients hospitalized with severe respiratory illness in South Africa, 2012–2015 date: 2021-09-16 journal: Influenza Other Respir Viruses DOI: 10.1111/irv.12905 sha: 1e4643887d6be2240a778753e5871c276720b05d doc_id: 964054 cord_uid: gdkph7hj BACKGROUND: We aimed to describe the prevalence of human respiratory syncytial virus (HRSV) and evaluate associations between HRSV subgroups and/or genotypes and epidemiologic characteristics and clinical outcomes in patients hospitalized with severe respiratory illness (SRI). METHODS: Between January 2012 and December 2015, we enrolled patients of all ages admitted to two South African hospitals with SRI in prospective hospital‐based syndromic surveillance. We collected respiratory specimens and clinical and epidemiological data. Unconditional random effect multivariable logistic regression was used to assess factors associated with HRSV infection. RESULTS: HRSV was detected in 11.2% (772/6908) of enrolled patients of which 47.0% (363/772) were under the age of 6 months. There were no differences in clinical outcomes of HRSV subgroup A‐infected patients compared with HRSV subgroup B‐infected patients but among patients aged <5 years, children with HRSV subgroup A were more likely be coinfected with Streptococcus pneumoniae (23/208, 11.0% vs. 2/90, 2.0%; adjusted odds ratio 5.7). No significant associations of HRSV A genotypes NA1 and ON1 with specific clinical outcomes were observed. CONCLUSIONS: While HRSV subgroup and genotype dominance shifted between seasons, we showed similar genotype diversity as noted worldwide. We found no association between clinical outcomes and HRSV subgroups or genotypes. 11.0% vs. 2/90, 2.0%; adjusted odds ratio 5.7). No significant associations of HRSV A genotypes NA1 and ON1 with specific clinical outcomes were observed. Conclusions: While HRSV subgroup and genotype dominance shifted between seasons, we showed similar genotype diversity as noted worldwide. We found no association between clinical outcomes and HRSV subgroups or genotypes. coinfection was found to negatively affect disease outcomes including increased odds of hospitalization. 2 HRSV is divided into two phylogenetically distinct subgroups (HRSV A and B), and these are further classified into multiple distinct genotypes based on sequence variability in the C-terminus of the envelope glycoprotein G (G protein). [4] [5] [6] [7] Since 2002, novel genotype BA, and since 2009 novel genotype ON1, displaying 60-and 72-nucleotide sequence duplications (HRSV subgroups B and A, respectively) within the second variable domain of the C-terminus have emerged. 4, [7] [8] [9] [10] [11] [12] [13] To date, these novel genotypes have disseminated globally, becoming the dominant genotypes in circulation. 4, [7] [8] [9] [10] 14 Contrasting findings have found no clear consensus between HRSV subgroups/genotypes and clinical outcomes. 4, [7] [8] [9] [10] [11] [12] 15 Inconsistencies observed between studies may be due to small sample sizes and geographic variances in population diversity and herd immunity, which could predispose to or protect individuals from adverse clinical outcomes. While no HRSV vaccines are currently available, global HRSV surveillance aided the development of multiple vaccine candidates that are in various stages of evaluation. 16 The high degree of sequence variance and complex circulation patterns of HRSV resulted in challenges for development of an effective HRSV vaccine. 13, [16] [17] [18] [19] These challenges include global and regional gaps in knowledge of HRSV epidemiology, subgroup and genotype geographic circulation patterns, target patient demographics, and outcomes for HRSVassociated clinical illness. 16 Regular updates of these knowledge gaps provide an information baseline that can be used to evaluate regional vaccine effectiveness when implemented and can inform vaccine formulation suitability and timing. In this study, we aimed to describe the seasonal patterns and prevalence of HRSV subgroups and genotypes among hospitalized patients with severe respiratory illness (SRI) in South Africa, from 2012 through 2015. We also aimed to compare the associations of HRSV subgroups and genotypes with epidemiologic characteristics and clinical outcomes. We enrolled participants in a prospective hospital-based SRI surveillance program from 01 January 2012 through 31 December 2015 at Edendale and Klerksdorp-Tshepong Hospitals situated in periurban areas in the subtropical KwaZulu-Natal and temperate North West Provinces of South Africa, respectively. The SRI case definition included hospitalized individuals of any age with illness onset of any duration prior to admission meeting age-specific inclusion criteria. Children aged 2 days to <3 months included any hospitalized patient with diagnosis of suspected sepsis or physician-diagnosed lower respiratory tract infection. 20 Children aged 3 months to <5 years included any hospitalized patient with physician-diagnosed lower respiratory tract infection, including bronchitis, bronchiolitis, pneumonia, and pleural effusion. 20 Individuals aged ≥5 years included any hospitalized patient presenting with lower respiratory tract infection with temperature ≥38 C or history of fever and cough. 20 Respiratory samples (nasopharyngeal aspirates for children <5 years of age and combined nasopharyngeal and oropharyngeal swabs from individuals ≥5 years of age) were collected and placed in universal transport medium (Copan, California, USA), stored at 4 C-8 C and transported within 72 h of collection to the National Institute for Communicable Diseases (NICD), Johannesburg, South Africa, for testing. 20 Whole blood samples (EDTA) were collected from consenting patients for the detection of Streptococcus pneumoniae (S. pneumoniae) by lytA polymerase chain reaction (PCR). HIV infection status was obtained from a combination of two sources: (i) patient clinical records and (ii) for consenting patients, dried blood spots that were tested by enzyme-linked immunosorbent assay (ELISA) for patients aged ≥18 months and PCR for children aged <18 months if the ELISA was reactive or exposure status was unknown. and F1 reverse primers as described. 25 HRSV-positive samples with insufficient volume or positives with cycle threshold (Ct)-values of >35 were not PCR amplified for sequencing as they were unlikely to successfully amplify. PCR products were analyzed and viewed following gel electrophoresis on a 1% agarose gel and purified using the The SRI surveillance protocol was reviewed and approved by the Table 1) . HRSV-positive children were less likely to be admitted to the intensive care unit (ICU) (aOR: 0.4), to be malnourished (aOR: 0.5), be HIV infected (aOR: 0.4), and be coinfected with influenza viruses (aOR: 0.2), rhinoviruses (aOR: 0.4), enteroviruses (aOR: 0.6), hMPV (aOR: 0.1), and PIV 1-3 (aOR: 0.2) than HRSV-negative children ( (Table 3) . No statistically significant differences were found between HRSV A and HRSV B positive individuals aged ≥5 years (Table S1 ). (Table 4) . Note: CI = confidence interval; ICU = intensive care unit; n/N = sample size/population size. This study builds upon our understanding of the clinical and epidemiological relevance of HRSV, its subgroups, and genotypes among patients hospitalized with SRI in South Africa. Changes in HRSV diversity over the study period demonstrated the presence and dominance of similar subgroups and genotypes found elsewhere in the world. This may suggest that no region-specific considerations will be required when selecting appropriate vaccine target strains. Furthermore, we showed that the youngest age group (<6 months), which demonstrated the highest HRSV infection prevalence (47%) would benefit most from HRSV vaccine implementation, similar to findings from previous studies from South Africa (55%). 2, 50 While no significant differences were found between the clinical outcomes and underlying illnesses associated with HRSV A and B infection or between HRSV A genotypes NA1 and ON1, a statistically significant association between HRSV A and S. pneumoniae coinfection in young children warrants further investigation of disease outcomes. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the funding agencies. We would like to thank the SRI surveillance teams in Edendale and Klerksdorp-Tshepong Hospitals for their contributions to this study. This work was supported by funds from the United States Centers for Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children Respiratory syncytial virus in adults with severe acute respiratory illness in a high HIV prevalence setting Genetic variability of human respiratory syncytial virus A strains circulating in Ontario: a novel genotype with a 72 nucleotide G gene duplication Displacement of predominant respiratory syncytial virus genotypes in Malaysia between Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America Ten years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide duplication in the G protein gene Rapid spread and diversification of respiratory syncytial virus genotype ON1 Molecular evolution of human respiratory syncytial virus attachment glycoprotein (G) gene of new genotype ON1 and ancestor NA1. Infection, Genetics and Evolution Novel respiratory syncytial virus subtype ON1 among children Molecular evolution of respiratory syncytial virus subgroup A genotype NA1 and ON1 attachment glycoprotein (G) gene in central Vietnam Genetic diversity and evolutionary insights of respiratory syncytial virus A ON1 genotype: global and local transmission dynamics Characteristics and their clinical relevance of respiratory syncytial virus types and genotypes circulating in northern Italy in five consecutive winter seasons Natural history of human respiratory syncytial virus inferred from phylogenetic analysis of the attachment (G) glycoprotein with a 60-nucleotide duplication How respiratory syncytial virus genotypes influence the clinical course in infants hospitalized for bronchiolitis Respiratory syncytial virus vaccines: are we making progress? Replacement of previously circulating respiratory syncytial virus subtype B strains with the BA genotype in South Africa Genetic variability of group A human respiratory syncytial virus strains circulating in Germany from 1998 to Replacement and positive evolution of subtype A and B respiratory syncytial virus Gprotein genotypes from 1997-2012 in South Africa The effects of the attributable fraction and the duration of symptoms on burden estimates of influenza-associated respiratory illnesses in a high HIV prevalence setting Respiratory viral coinfections identified by a 10-plex real-time reverse-transcription polymerase chain reaction assay in patients hospitalized with severe acute respiratory illness-South Africa Simultaneous detection, subgrouping, and quantitation of respiratory syncytial virus A and B by real-time PCR Molecular quantification of respiratory syncytial virus in respiratory samples: reliable detection during the initial phase of infection Analysis of respiratory syncytial virus genetic variability with amplified cDNAs Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community MUSCLE: multiple sequence alignment with high accuracy and high throughput RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies Temperature, humidity, and ultraviolet B radiation predict community respiratory syncytial virus activity Comparative global epidemiology of influenza, respiratory syncytial and parainfluenza viruses Performance of surveillance case definitions in detecting respiratory syncytial virus infection among young children hospitalized with severe respiratory illness-South Africa Burden of severe respiratory syncytial virus disease among 33-35 weeks' gestational age infants born during multiple respiratory syncytial virus seasons Intensive care unit admission and death rates of infants admitted with respiratory syncytial virus lower respiratory tract infection in Mexico Severity of respiratory syncytial virus lower respiratory tract infection with viral coinfection in HIVuninfected children The role of influenza, RSV and other common respiratory viruses in severe acute respiratory infections and influenza-like illness in a population with a high HIV sero-prevalence The adaptive immune response to respiratory syncytial virus Respiratory syncytial virus infection in an adult with AIDS Respiratory syncytial virus pneumonia in a human immunodeficiency virus-infected man Respiratory syncytial virus infections in hospitalized infants: association between viral load, virus subgroup, and disease severity Severity of respiratory syncytial virus disease related to type and genotype of virus and to cytokine values in nasopharyngeal secretions Clinical profiles of respiratory syncytial virus subtypes A and B among children hospitalized with bronchiolitis Correlation between respiratory syncytial virus genotype and severity of illness Variation in severity of respiratory syncytial virus infections with subtype Clinical severity of respiratory syncytial virus group A and B infection in Sydney, Australia Does respiratory syncytial virus subtype influences the severity of acute bronchiolitis in hospitalized infants Severity of respiratory syncytial virus infection is related to virus strain Streptococcus pneumoniae colonization of the nasopharynx is associated with increased severity during respiratory syncytial virus infection in young children Respiratory syncytial virus increases the virulence of Streptococcus pneumoniae by binding to penicillin binding protein 1a. A new paradigm in respiratory infection Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data Risk factors associated with hospitalisation for influenza-associated severe acute respiratory illness in South Africa: a case-population study The burden of respiratory syncytial virus infection in young children Additional supporting information may be found in the online version of the article at the publisher's website.